Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBT Margin (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed EBT Margin for 4 consecutive years, with 14.35% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 1495105.0% to 14.35% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 28.77% through Dec 2025, up 7860.0% year-over-year, with the annual reading at 28.77% for FY2025, 4567.0% up from the prior year.
  • EBT Margin hit 14.35% in Q4 2025 for Axsome Therapeutics, up from 27.62% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 9.13% in Q1 2023 to a low of 14965.4% in Q4 2024.
  • Historically, EBT Margin has averaged 1114.76% across 4 years, with a median of 91.14% in 2024.
  • Biggest five-year swings in EBT Margin: plummeted -1482703bps in 2024 and later skyrocketed 1495105bps in 2025.
  • Year by year, EBT Margin stood at 251.29% in 2022, then surged by 45bps to 138.37% in 2023, then plummeted by -10716bps to 14965.4% in 2024, then skyrocketed by 100bps to 14.35% in 2025.
  • Business Quant data shows EBT Margin for AXSM at 14.35% in Q4 2025, 27.62% in Q3 2025, and 32.61% in Q2 2025.